Results of studies in patients with low- and intermediate-risk myelodysplastic syndrome (MDS) treated with hypomethylating agents (low dose azacytidine or decitabine) followed for a median of 18 months were presented at the Society of Hematologic Oncology meeting in Houston on September 9, 2016. Continue reading
Tag Archives: Cyclin D
Rexahn – 3 Novel Cancer Products in Development
I attended the Rexahn presentation at the Biotech Showcase on January 12-14, 2015. The company has 3 novel anti-cancer products in the clinic. Continue reading
Why more males develop brain tumors than females
It is widely known that brain tumors, in particular glioblastomas and medulloblastomas, affect males more than females. Moreover, given the age of onset and analysis of incidence by age, sex hormones have been ruled-out as the cause. Continue reading